On February 5, 2021, lisocabtagene maraleucel, an anti-CD19 autologous CAR-T therapy, was approved for the treatment of R/R large B-cell lymphoma after two or more lines of systemic therapy, which was based on the multicenter TRANSCEND trial. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.